Blueprint Medicines (BPMC) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.

15 analysts have issued twelve-month price targets for Blueprint Medicines' stock. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they expect the company's stock price to reach $74.89 in the next year. This suggests a possible upside of 28.1% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.

Blueprint Medicines' stock was trading at $43.81 at the beginning of the year. Since then, BPMC stock has increased by 33.5% and is now trading at $58.47.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our BPMC earnings forecast.

Blueprint Medicines Co. (NASDAQ:BPMC) issued its earnings results on Thursday, May, 4th. The biotechnology company reported ($2.15) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.51. The biotechnology company earned $63.29 million during the quarter, compared to the consensus estimate of $41.85 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 100.31% and a negative net margin of 284.02%. The company's revenue was up .9% on a year-over-year basis. During the same period last year, the company posted ($1.79) earnings per share.

ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), BlackRock Future Health ETF (BMED), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.59%), BlackRock Inc. (10.95%), Wellington Management Group LLP (8.50%), Price T Rowe Associates Inc. MD (8.18%), State Street Corp (4.56%) and JPMorgan Chase & Co. (2.57%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends.

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPMC stock can currently be purchased for approximately $58.47.

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.54 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.

The company employs 495 workers across the globe.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.